Data as of · ABT trades at $108.14 (+0.79% today) · Health Care sector.
ML Forecast (5-day)
39% bearish
Probability of beating the S&P 500 over 5 trading days
Q-Score
17/100
Grade D — "Sell" composite of 140+ signals
Analyst Target
$120.12
100 targets · $116.50–$122.33 · implied +11.1%
Next Earnings
2026-10-21
in 83 days — expect volatility
The ML model scores ABT on 54 live features, trained on 5,328 labeled outcomes and walk-forward validated. Biggest drivers of today's bearish call:
Across 100 price targets published in the last 90 days (latest 2026-07-29), the consensus for ABBOTT LABORATORIES is $120.12 — spanning $116.50 on the low end to $122.33 on the high end.
Next-period consensus: EPS n/a (as of 2030-12-31).
StoQuant publishes its full walk-forward accuracy, updated daily. Current hit rates across all scored signals:
| Signal | Window | Hit rate | Avg return | Observations |
|---|---|---|---|---|
| Fundamental Undervalue | 7d | 51.6% | +0.52% | 8,963 |
| Vc Intelligence | 7d | 50.0% | +0.60% | 16 |
| Insider Buying | 7d | 49.4% | +0.66% | 1,052 |
| Volume Spike | 7d | 49.4% | +0.25% | 6,072 |
See the full live track record → · How the model works
⚠ ABBOTT LABORATORIES reports earnings on 2026-10-21 — expect elevated volatility and a forecast refresh right after the report.
Compare ABT vs AZN head-to-head →
StoQuant's ML model estimates a 39% probability that ABBOTT LABORATORIES (ABT) outperforms the S&P 500 over the next 5 trading days — a bearish short-term signal. Wall Street's consensus 12-month price target is $120.12 from 100 analyst targets.
StoQuant's Q-Score rates ABT 17/100 (grade D, "Sell") and the 5-day ML signal is bearish at 39% probability. StoQuant publishes its full walk-forward track record at /proof — always check a forecaster's accuracy before acting.
The consensus analyst price target for ABBOTT LABORATORIES is $120.12, with a range of $116.50 to $122.33 across 100 recent analyst targets — an implied +11.1% move from the current price of $108.14.
Across StoQuant's walk-forward validated signal history, the fundamental undervalue signal hit its 7-day target in 51.6% of 8,963 observations (avg return +0.52%). Full methodology and live accuracy at /proof.
ABBOTT LABORATORIES is scheduled to report earnings on 2026-10-21. Expect elevated forecast volatility around the report.
Get ABT's forecast refreshed daily — plus the full signal stack.
ML forecasts, Q-Scores, insider clusters, and catalysts across 4,000+ tickers. Free screener.
Open the free screener Full ABT researchForecasts are probabilistic model outputs, not investment advice. Past accuracy does not guarantee future results. Methodology.